LT3099306T - Steroidinis junginys, skirtas panaudoti kepenų encefalopatijos gydymui - Google Patents

Steroidinis junginys, skirtas panaudoti kepenų encefalopatijos gydymui

Info

Publication number
LT3099306T
LT3099306T LTEP15705691.2T LT15705691T LT3099306T LT 3099306 T LT3099306 T LT 3099306T LT 15705691 T LT15705691 T LT 15705691T LT 3099306 T LT3099306 T LT 3099306T
Authority
LT
Lithuania
Prior art keywords
treatment
hepatic encephalopathy
steroid compound
steroid
compound
Prior art date
Application number
LTEP15705691.2T
Other languages
English (en)
Inventor
Magnus DOVERSKOG
Hanns MÖHLER
Vicente FELIPO
Torbjörn BÄCKSTRÖM
Original Assignee
Umecrine Cognition Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Umecrine Cognition Ab filed Critical Umecrine Cognition Ab
Publication of LT3099306T publication Critical patent/LT3099306T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016Disaccharides, e.g. lactose, lactulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LTEP15705691.2T 2014-01-29 2015-01-14 Steroidinis junginys, skirtas panaudoti kepenų encefalopatijos gydymui LT3099306T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1450089 2014-01-29
PCT/GB2015/050060 WO2015114308A1 (en) 2014-01-29 2015-01-14 Steroid compound for use in the treatment of hepatic encephalopathy

Publications (1)

Publication Number Publication Date
LT3099306T true LT3099306T (lt) 2019-03-12

Family

ID=52544513

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP15705691.2T LT3099306T (lt) 2014-01-29 2015-01-14 Steroidinis junginys, skirtas panaudoti kepenų encefalopatijos gydymui

Country Status (25)

Country Link
US (3) US20160339040A1 (lt)
EP (1) EP3099306B1 (lt)
JP (1) JP6543633B2 (lt)
KR (1) KR102324667B1 (lt)
CN (2) CN113185566A (lt)
AU (1) AU2015212606B2 (lt)
BR (1) BR112016017620A2 (lt)
CA (1) CA2935015C (lt)
CY (1) CY1121464T1 (lt)
DK (1) DK3099306T3 (lt)
ES (1) ES2714563T3 (lt)
HR (1) HRP20190251T1 (lt)
HU (1) HUE042242T2 (lt)
IL (1) IL246496B (lt)
LT (1) LT3099306T (lt)
ME (1) ME03351B (lt)
MX (1) MX2016008851A (lt)
PL (1) PL3099306T3 (lt)
PT (1) PT3099306T (lt)
RS (1) RS58375B1 (lt)
RU (1) RU2684616C2 (lt)
SI (1) SI3099306T1 (lt)
SM (1) SMT201900133T1 (lt)
TR (1) TR201901687T4 (lt)
WO (1) WO2015114308A1 (lt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015212606B2 (en) 2014-01-29 2019-11-21 Umecrine Cognition Ab Steroid compound for use in the treatment of hepatic encephalopathy
AR103384A1 (es) 2015-01-12 2017-05-03 Umecrine Cognition Ab 3a-ETINILO, 3b-HIDROXI, 5a-PREGNAN-20-OXIMA COMO MODULADOR DE GABA
US10278977B2 (en) 2016-06-06 2019-05-07 Umecrine Cognition Ab Methods for treating hypersomnolence
FI3668927T3 (fi) 2017-09-12 2024-04-05 Eth Zuerich Transmembraaniset ph-gradienttipolymeerit ammoniakin kvantifiointiin kehon nesteissä
BR112020010519A2 (pt) * 2017-11-27 2020-10-20 Umecrine Cognition Ab formulação farmacêutica de oxima de 3¿lfa-etinil-3¿eta-hidroxiandrostan-17-ona
EP4079307A1 (en) 2021-04-20 2022-10-26 Umecrine Cognition AB New medical use
US20230134958A1 (en) * 2021-10-29 2023-05-04 Umecrine Cognition Ab New medical treatment
EP4389129A1 (en) 2022-12-22 2024-06-26 Umecrine Cognition AB 3a-ethynyl-3beta hydroxyandrostan 17-one oxime for treating parkinson's disease and l-dopa-induced dyskinesia
WO2025252725A1 (en) 2024-06-04 2025-12-11 Umecrine Cognition Ab Novel pharmaceutical formulation of golexanolone
WO2025252724A1 (en) 2024-06-04 2025-12-11 Umecrine Cognition Ab Novel pharmaceutical formulation of golexanolone

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2713061A (en) 1951-04-06 1955-07-12 Schering Ag 3-methyl androstanes
FR1463755A (fr) 1960-01-26 1966-07-22 Nouveaux stéroïdes de la série de l'androstane et leur procédé de préparation
US3173932A (en) 1962-11-02 1965-03-16 American Cyanamid Co 15-substituted estra-1, 3, 5(10)-trienes
FR2685332A1 (fr) 1991-12-20 1993-06-25 Roussel Uclaf Nouveaux 19-nor sterouides ayant en position 11beta une chaine thiocarbonee, leur procede de preparation et les intermediaires et leur application a titre de medicaments.
AU698834B2 (en) 1993-05-24 1998-11-12 Purdue Pharma Ltd. Methods and compositions for inducing sleep
CN1270718C (zh) 1998-03-11 2006-08-23 托布乔恩·贝克斯托罗姆 表别孕烷醇酮在制备治疗甾族化合物诱导的疾病的药物中的应用
WO2002100877A1 (en) 2001-06-11 2002-12-19 Southwest Foundation For Biomedical Research Novel 2-alkoxyestradiol analogs with antiproliferative and antimitotic activity
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
SE0104423D0 (sv) * 2001-12-27 2001-12-27 Umecrine Ab Pregnane steroids and their use in the treatment of CNS disorders
SG158073A1 (en) 2004-11-26 2010-01-29 Ucl Business Plc Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy
WO2007103162A2 (en) * 2006-03-01 2007-09-13 Samaritan Pharmaceuticals, Inc. Structure based drug design of steroidogenesis inhibitors
DK2097437T3 (en) 2006-11-21 2015-06-29 Umecrine Cognition Ab THE USE OF PREGNANCY AND ANDROSTANOSTEROIDS FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CNS DISEASES
GB0711948D0 (en) 2007-06-20 2007-08-01 Bionature E A Ltd Neurosteriod compounds
CN101585862B (zh) * 2008-05-20 2014-12-17 梅克芳股份公司 甾族化合物
HUE048293T2 (hu) * 2008-10-02 2020-07-28 Salix Pharmaceuticals Ltd Eljárások hepatikus enkefalopátia kezelésére
EA201691430A1 (ru) 2009-06-08 2017-02-28 ЮСиЭл БИЗНЕС ПиЭлСи Лечение портальной гипертензии и восстановление функции печени с помощью l-орнитинфенилацетата
EP3019074B1 (en) 2013-09-30 2018-08-29 Horizon Therapeutics, LLC Diagnosing, grading, monitoring, and treating hepatic encephalopathy
AU2015212606B2 (en) 2014-01-29 2019-11-21 Umecrine Cognition Ab Steroid compound for use in the treatment of hepatic encephalopathy

Also Published As

Publication number Publication date
EP3099306B1 (en) 2018-12-12
KR20160105922A (ko) 2016-09-07
ME03351B (me) 2019-10-20
ES2714563T3 (es) 2019-05-29
EP3099306A1 (en) 2016-12-07
US20160339040A1 (en) 2016-11-24
CN113185566A (zh) 2021-07-30
JP2017507113A (ja) 2017-03-16
DK3099306T3 (en) 2019-03-18
SMT201900133T1 (it) 2019-05-10
RS58375B1 (sr) 2019-03-29
US10342804B2 (en) 2019-07-09
MX2016008851A (es) 2017-03-23
AU2015212606A1 (en) 2016-07-14
PT3099306T (pt) 2019-03-21
IL246496B (en) 2019-09-26
RU2016127558A (ru) 2018-03-05
CA2935015C (en) 2022-05-31
SI3099306T1 (sl) 2019-03-29
HRP20190251T1 (hr) 2019-04-05
IL246496A0 (en) 2016-08-31
PL3099306T3 (pl) 2019-06-28
KR102324667B1 (ko) 2021-11-10
WO2015114308A1 (en) 2015-08-06
US9801894B2 (en) 2017-10-31
RU2016127558A3 (lt) 2018-09-27
WO2015114308A8 (en) 2016-07-21
BR112016017620A2 (pt) 2017-08-08
CA2935015A1 (en) 2015-08-06
US20170056416A1 (en) 2017-03-02
RU2684616C2 (ru) 2019-04-10
CN106163528A (zh) 2016-11-23
US20180015103A1 (en) 2018-01-18
AU2015212606B2 (en) 2019-11-21
HUE042242T2 (hu) 2019-06-28
TR201901687T4 (tr) 2019-02-21
CY1121464T1 (el) 2020-05-29
JP6543633B2 (ja) 2019-07-10
NZ721622A (en) 2020-11-27

Similar Documents

Publication Publication Date Title
IL285553A (en) Use of prg4 as an anti-inflammatory agent
IL250685A0 (en) Medicinal substance induces cytotoxicity
IL246496A0 (en) A steroid compound for use in the treatment of hepatic encephalopathy
PT3015526T (pt) Composição à base de hidrofluoroolefina e sua utilização
IL251371A0 (en) Cortexolone 17alpha-benzoate for use in the treatment of tumors
GB201400442D0 (en) Compositions for use in the treatment of ulcerative colitis
IL248767B (en) Trimethoxyphenyl-benzaimidazole compounds for cancer treatment
EP3215157B8 (en) Apilimod for use in the treatment of melanoma
ZA201608784B (en) Fused triterpene compounds and uses thereof
IL246855A0 (en) Materials for use in the treatment of retinitis
PL3129398T3 (pl) Nowe środki medyczne i ich zastosowanie
SG11201703577RA (en) Bathroom unit
IL249075B (en) agent for fluoroalkylation
EP3145525A4 (en) Use of microperoxidases for the treatment of carboxyhemoglobinemia
SG11201607674SA (en) Retinoic-acid-producing agent
GB201418541D0 (en) Materials for use with general hyperthermia treatment
GB201401124D0 (en) Anti-inflammatory solution
PL3370727T3 (pl) Nieulegające biokonwersji c3-podstawione pochodne pregnenolonu do zastosowania w leczeniu zaburzeń związanych z nadużywaniem substancji
GB201404124D0 (en) The theory of european monetary
ZA201408464B (en) Composition for the use in treatment of asthma
GB201513410D0 (en) Dignity shower unit
GB201409241D0 (en) Therapeutic agents